Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial.

News | Pharmaceuticals | March 28, 2020 | Dave Fornell, Editor
March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran...
Find more news from ACC 2020.Women carry heavier burden of chest pain, but less artery narrowing according to data in a substudy of the ISCHEMIA Trial. #ACC20 #ACC2020 #ISCHEMIA

Women carry heavier burden of chest pain, but less artery narrowing, according to data in a substudy from the ISCHEMIA Trial. 
 

News | Womens Cardiovascular Health | March 28, 2020
March 28, 2020 — Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia)...
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis. #ACC20 #ACC2020
News | Heart Failure | March 28, 2020
March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of...
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to...
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

News | Peripheral Artery Disease (PAD) | March 28, 2020
March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with...
News | Coronavirus (COVID-19) | March 27, 2020
March 27, 2020 — The European Society of Cardiology (ESC) has created a novel coronavirus resource page with...
Italian Cardiologist Maurizio Galderisi Died From COVID-19, #coronavirus #COVID19
News | Coronavirus (COVID-19) | March 27, 2020
March 27, 2020 — In Italy today, novel coronavirus (COVID-19) claimed the life of well known cardiologist Maurizio...
Videos | Coronavirus (COVID-19) | March 26, 2020
Regina Druz, M.D., FASNC, a member of the American Society of Nuclear Cardiology (ASNC) Board of Directors, chairwomen...
Videos | FFR Technologies | March 26, 2020
James Udelson, M.D., chief of the division of cardiology, Tufts Medical Center, explains how cardiac computed...
The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

News | Heart Valve Technology | March 25, 2020
  March 25, 2020 — CroiValve announced the successful first human use of its Duo Tricuspid Coaptation Valve technology...
News | Coronavirus (COVID-19) | March 25, 2020 | Dave Fornell, Editor
March 25, 2020 — The U.S. Food and Drug Administration (FDA) said it is taking action to increase U.S. supplies of...
Hydroxychloroquine causes prolonged QT intervals and cardiac arrhythmias, so this needs to be considered in patients being treated with this drug for COVID-19. #COVID19 #SARScov2 #coronavirus

Hydroxychloroquine causes prolonged QT intervals and cardiac arrhythmias, so this needs to be considered in patients being treated with this drug for COVID-19.

Feature | Coronavirus (COVID-19) | March 24, 2020 | Marianne Pop, Pharm.D, BCPS
It has been more than three months since the word coronavirus was uttered on everyone’s lips and all over the social...
Videos | Structural Heart Occluders | March 24, 2020
Interview with Carey Kimmelstiel, M.D., FACP, FACC, director, cardiac catheterization laboratory, director,...
SCAI cancelled due to COVID-19, SARS-CoV-2, coronavirus. #COVID19 #coronavirus #coronavirusupdate #SARScov2
News | Coronavirus (COVID-19) | March 23, 2020
March 23, 2020 — As the novel coronavirus (COVID-19, SARS-cov-2) continues to spread, the Society for Cardiovascular...
Videos | Coronavirus (COVID-19) | March 17, 2020
Interview with Mike Stone, M.D., an emergency physician at Northwest Acute Care Specialists in Portland, Ore., director...